Suzhou Keruisi Pharmaceutical

Suzhou Keruisi Pharmaceutical is a clinical-stage biotechnology company headquartered in the Suzhou Industrial Park, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology. The company focuses on precision medicine, targeting specific genetic alterations that drive tumor growth, such as FGFR and RET mutations. Its lead candidate, CRS-001, is a selective FGFR inhibitor currently in Phase 2 clinical trials for indications including cholangiocarcinoma and urothelial carcinoma. Keruisi aims to address significant unmet medical needs by advancing a pipeline of targeted therapies designed to improve outcomes for cancer patients. The company leverages its internal research capabilities and strategic location in China's biotech hub to accelerate drug development. Through its commitment to innovation, Suzhou Keruisi is positioned as an emerging player in the Chinese oncology market.